Patents & FDA Regulation
of Pharmaceutical Products


Wednesday, Oct. 22, 2020 • 1:30 p.m. - 3:00 p.m. EDT

Do you know how to talk to your patent attorneys and IP specialists about relevant regulatory and compliance mandates? Has your team considered the importance of exclusivity? Are you moving down one of the two major pathways — Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA) — to enable generic and biosimilar drug development?

These questions, and the way they’ll help advance your patent and intellectual property needs, might just be the key to your product’s success.

Through the Patents & FDA Regulation of Pharmaceutical Products webinar on Oct. 22, you’ll get a broad look at how patents and IP relate to drug development and discover how these processes work to provide market exclusivity, keeping competitors at bay. 

Patent attorney Joanna Brougher will share the strategies companies can use to develop strong patent portfolios. She’ll also explore how to protect your product against competitors by supplementing those patent strategies with FDA exclusivities.

Key Webinar Takeaways:

  • How patents and the FDA regulatory process overlap, including during the drug approval process

  • The differences between patent exclusivity and FDA exclusivity, including compliance

  • The various types of FDA exclusivity available and what that means to regulatory specialists

  • Strategies for using exclusivity to build a strong patent portfolio and protect against competitors

  • Reasons drugs manufacturers should understand strategic patent processes

  • Potential weaknesses in patents and how FDA exclusivity can help maintain market protection

  • How orphan drug and pediatric exclusivity can encourage drug development

Building a strong patent portfolio and gaining a deep understanding of FDA exclusivity can help protect the drugs you’re developing from competitors and provide a path toward its market success. Ensure you and your team understand these processes with this essential webinar on patents and IP issues.

Join us by registering today.

Webinar plus Recording & Transcript Bundle
Learn more

$487

add to cart

Webinar only
Learn more

$287

add to cart

24/7 Encore plus Recording & Transcript Bundle
Learn more

$487

add to cart

24/7 Encore Presentation
Learn more

$287

add to cart

Webinar Recording & Transcript Bundle
Learn more

$287

add to cart

 

Who Will Benefit

  • Biotech and pharmaceutical companies
  • C-level executives
  • Regulatory professionals
  • Quality professionals
  • Compliance specialists
  • GMP professionals
  • Inspections and audit staff
  • Post-market safety staff
  • Submissions and approvals professionals
  • Research and development staff
  • Commercial operations staff

 

Meet Your Presenter

Joanna Brougher

Owner and Principal
BioPharma Law Group PLLC

Joanna Brougher is a patent attorney who focuses on all service aspects in the areas of biotechnology, pharmaceuticals and medical devices, including patentability opinions, due diligence, patent drafting, domestic and foreign patent prosecution, development and management of patent portfolios, and general counseling. She assists clients through all phases of a product’s lifecycle, from conception to commercialization. She also has experience counseling clients on the Hatch-Waxman Act and monitors developments involving biosimilars under the Biologics Price Competition and Innovation Act.

MII logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 | Fax 703.538.7676 | Toll free 888.838.5578 | Email customerservice@fdanews.com

© 2020 FDAnews